primary antibodies against cd44  (Proteintech)

Journal: Journal of Translational Medicine

Article Title: Integration of angiogenesis and programmed cell death mechanisms unveils potential diagnostic and therapeutic targets in spinal cord injury

doi: 10.1186/s12967-025-07405-2

Figure Lengend Snippet: mRNA-drug interaction network and molecular docking analysis of hub genes with acetaminophen. A-C . mRNA-drugs network of hub genes. D . A molecular docking diagram of Cd44 and acetaminophen. E . A molecular docking diagram of tnf and acetaminophen

Article Snippet: Primary antibodies against Cd44 (Proteintech Group, 1:1000), Icam1 (Proteintech Group, 1:1000), Tnf (Proteintech Group, 1:1000), Cd31 (Proteintech Group, 1:1000), N-Gsdmd (Proteintech Group, 1:2000) were incubated overnight at 4 °C, followed by HRP-conjugated secondary antibodies.

Techniques:

Journal: Journal of Translational Medicine

Article Title: Integration of angiogenesis and programmed cell death mechanisms unveils potential diagnostic and therapeutic targets in spinal cord injury

doi: 10.1186/s12967-025-07405-2

Figure Lengend Snippet: Single-cell transcriptomic profiling and hub-gene localization in SCI. A-B . UMAP visualization of single-cell RNA sequencing data, showing 22 transcriptionally distinct clusters further classified into 13 major cell types based on canonical markers. C . Stacked bar plot illustrating the proportions of each cell type in control versus SCI samples. D . Bubble plot displaying cluster-specific marker genes. E . Bubble plot showing expression of hub genes Cd44, Tnf, and Icam1 between control and sci groups, with dot size representing the percentage of cells expressing the gene and color indicating average expression level. F-H . Density plots depicting the distribution of hub genes across the umap space

Article Snippet: Primary antibodies against Cd44 (Proteintech Group, 1:1000), Icam1 (Proteintech Group, 1:1000), Tnf (Proteintech Group, 1:1000), Cd31 (Proteintech Group, 1:1000), N-Gsdmd (Proteintech Group, 1:2000) were incubated overnight at 4 °C, followed by HRP-conjugated secondary antibodies.

Techniques: RNA Sequencing, Control, Marker, Expressing

Journal: Journal of Translational Medicine

Article Title: Integration of angiogenesis and programmed cell death mechanisms unveils potential diagnostic and therapeutic targets in spinal cord injury

doi: 10.1186/s12967-025-07405-2

Figure Lengend Snippet: Mendelian randomization (MR) analysis of hub genes and SCI risk. A . TheMendelianrandomization of CD44 and SCl. B . TheMendelianrandomization of ICAM1 and SCl. C . TheMendelianrandomization of TNF and SCl. Odds ratios (ORs) with 95% confidence intervals are presented, with significant results highlighted in blue. No evidence of horizontal pleiotropy or heterogeneity was detected, supporting causal relationships between hub-gene variants and SCI

Article Snippet: Primary antibodies against Cd44 (Proteintech Group, 1:1000), Icam1 (Proteintech Group, 1:1000), Tnf (Proteintech Group, 1:1000), Cd31 (Proteintech Group, 1:1000), N-Gsdmd (Proteintech Group, 1:2000) were incubated overnight at 4 °C, followed by HRP-conjugated secondary antibodies.

Techniques:

Journal: Journal of Translational Medicine

Article Title: Integration of angiogenesis and programmed cell death mechanisms unveils potential diagnostic and therapeutic targets in spinal cord injury

doi: 10.1186/s12967-025-07405-2

Figure Lengend Snippet: Validation of three hub genes at different time points after SCI. ( A–C ) mRNA expression of Cd44 at 1, 3, and 7 days post-SCI and in control group; ( d ) Western blot analysis of Cd44 protein expression and quantification. ( E–G ) mRNA expression of Icam1 at 1, 3, and 7 days post-SCI and in control group; ( H ) Western blot analysis of Icam1 protein expression and quantification. ( I–K ) mRNA expression of Tnf at 1, 3, and 7 days post-SCI and in control group; ( L ) Western blot analysis of Tnf protein expression and quantification. mRNA expression was normalized to GAPDH, and protein levels were normalized to β-actin. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: Primary antibodies against Cd44 (Proteintech Group, 1:1000), Icam1 (Proteintech Group, 1:1000), Tnf (Proteintech Group, 1:1000), Cd31 (Proteintech Group, 1:1000), N-Gsdmd (Proteintech Group, 1:2000) were incubated overnight at 4 °C, followed by HRP-conjugated secondary antibodies.

Techniques: Biomarker Discovery, Expressing, Control, Western Blot

Journal: Journal of Translational Medicine

Article Title: Integration of angiogenesis and programmed cell death mechanisms unveils potential diagnostic and therapeutic targets in spinal cord injury

doi: 10.1186/s12967-025-07405-2

Figure Lengend Snippet: In vivo validation of acetaminophen treatment in SCI mice. A . Mechanical withdrawal thresholds (MPT) measured at baseline (0 d) and 1, 3, and 7 days after SCI. Acetaminophen significantly increased thresholds at day 7 compared with sci controls. B . Thermal pain thresholds assessed using the tail-flick test. Acetaminophen significantly prolonged latency at day 3 (*** p < 0.001) and remained elevated at day 7 (** p < 0.01). C-E . Western blot analysis and quantification of Cd44 and Tnf expression, showing significant reduction after acetaminophen treatment (* p < 0.05). F-H . Western blot analysis and quantification of Cd31 and N-Gsdmd expression, showing significant difference between groups (* p < 0.05,** p < 0.01). β-actin served as loading control

Article Snippet: Primary antibodies against Cd44 (Proteintech Group, 1:1000), Icam1 (Proteintech Group, 1:1000), Tnf (Proteintech Group, 1:1000), Cd31 (Proteintech Group, 1:1000), N-Gsdmd (Proteintech Group, 1:2000) were incubated overnight at 4 °C, followed by HRP-conjugated secondary antibodies.

Techniques: In Vivo, Biomarker Discovery, Tail Flick Test, Western Blot, Expressing, Control